Finally, we identified four potential drug targets using GEMs, repositioned mitotane for treatment of ccRCC by inhibiting one of the identified drug targets, SOAT1 and validated its drug effect based on in vitro experiments. The gene discussed is SOAT1; the disease is nonpapillary renal cell carcinoma.